TABLE 3.
Patient demographics and BM characteristics in the population who experienced SREs.
| Characteristics | Frequency | Percentage |
| Age at BM diagnosis (n = 137) | ||
| Median, 59 years | ||
| Sex (n = 137) | ||
| Male | 89 | 65.0 |
| Female | 48 | 35.0 |
| BRAF status (n = 131) | ||
| Mutated | 71 | 54.2 |
| Wild type | 60 | 45.8 |
| NRAS status (n = 27) | ||
| Mutated | 11 | 40.7 |
| Wild type | 16 | 59.3 |
| LDH levels at BM diagnosis (n = 109) | ||
| ≤2 × ULN | 73 | 67.0 |
| >2 × ULN | 36 | 33.0 |
| Calcaemia at BM diagnosis (n = 104) | ||
| ≤ ULN | 93 | 89.4 |
| > ULN | 11 | 10.6 |
| BM and melanoma diagnosis (n = 137) | ||
| Synchronous | 18 | 13.1 |
| Metachronous | 119 | 86.9 |
| SRE and BM diagnosis (n = 129) | ||
| Synchronous | 38 | 29.5 |
| Metachronous | 91 | 70.5 |
| Localization of BM (n = 133) | ||
| Axial | 74 | 55.6 |
| Appendicular | 17 | 12.8 |
| Both | 42 | 31.6 |
| Number of BM (n = 134) | ||
| <5 | 89 | 66.4 |
| ≥5 | 45 | 33.6 |
| Presence of extraosseous mts (n = 137) | ||
| No | 7 | 5.1 |
| Yes | 130 | 94.9 |
| Use of BTA (n = 137) | ||
| No | 63 | 46 |
| Bisphosphonates | 67 | 48.9 |
| Denosumab | 7 | 5.1 |
BM, bone metastases; BTA, bone-targeting agents; LDH, lactate dehydrogenase; mts, metastases; SRE, skeletal-related events; ULN, upper limit of normal.